Skip to main content

RxNews®

Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.

Wyost® (denosumab-bbdz) – New first-time interchangeable biosimilar approval

March 5, 2024 - The FDA approved Sandoz’s Wyost (denosumab-bbdz), biosimilar and interchangeable to Amgen’s Xgeva® (denosumab).

Download PDF

Rx navigation